PMID- 19184059
OWN - NLM
STAT- MEDLINE
DCOM- 20090610
LR  - 20220330
IS  - 1432-1262 (Electronic)
IS  - 0179-1958 (Linking)
VI  - 24
IP  - 6
DP  - 2009 Jun
TI  - A meta-analysis of randomized controlled trials comparing chemotherapy plus 
      bevacizumab with chemotherapy alone in metastatic colorectal cancer.
PG  - 677-85
LID - 10.1007/s00384-009-0655-9 [doi]
AB  - PURPOSE: Bevacizumab has demonstrated survival benefit in metastatic colorectal 
      cancer (mCRC) patients when combined with chemotherapy. Several randomized 
      clinical studies have evaluated bevacizumab in combination with chemotherapy. 
      Meta-analysis was performed to better assess the efficacy and safety of 
      bevacizumab with chemotherapy for mCRC. MATERIALS AND METHODS: Five clinical 
      trials randomizing a total of 3,103 mCRC patients to chemotherapy alone or to the 
      combined treatment of chemotherapy plus bevacizumab were identified. The efficacy 
      data included progression-free survival (PFS), overall survival (OS), and overall 
      response rate (ORR), and the safety data contained the 60-day all-cause mortality 
      rate, adverse events (AEs), and specific toxicity such as hypertension, 
      thrombosis, bleeding, proteinuria, gastrointestinal perforation, diarrhea, and 
      leucopenia. RESULT: There was a significant PFS benefit (P = 0.00; hazards ratio 
      [HR] = 0.66) and OS benefit (P = 0.00; HR = 0.77) in favor of the combined 
      treatment. The ORR was significantly higher on the bevacizumab-containing arm (P 
      = 0.021; relative risk [RR] = 1.5), while CR was comparable between the two arms 
      (P = 0.09). A higher incidence of grade 3/4 AEs, grade 3/4 hypertension, grade 
      3/4 thromboembolic/thrombotic events, grade 3/4 bleeding, and gastrointestinal 
      perforation was associated with the bevacizumab group. The two treatment groups 
      were similar in terms of grade 3/4 proteinuria, grade 3/4 leukopenia, grade 3/4 
      diarrhea, and the 60-day all-cause mortality rate. CONCLUSION: The addition of 
      bevacizumab to chemotherapy confers a clinically meaningful and statistically 
      significant improvement in OS, PFS, and ORR. Its side effects are predictable and 
      manageable and do not compound the incidence or severity of toxicities from 
      chemotherapy.
FAU - Cao, Yunfei
AU  - Cao Y
AD  - Department of Colorectal and Anal Surgery, First Affiliated Hospital, Guangxi 
      Medical University, Nanning, Guangxi, People's Republic of China.
FAU - Tan, Aihua
AU  - Tan A
FAU - Gao, Feng
AU  - Gao F
FAU - Liu, Lidan
AU  - Liu L
FAU - Liao, Cun
AU  - Liao C
FAU - Mo, Zengnan
AU  - Mo Z
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20090130
PL  - Germany
TA  - Int J Colorectal Dis
JT  - International journal of colorectal disease
JID - 8607899
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Bevacizumab
MH  - Colorectal Neoplasms/*drug therapy/mortality/*pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Randomized Controlled Trials as Topic
EDAT- 2009/02/03 09:00
MHDA- 2009/06/11 09:00
CRDT- 2009/02/03 09:00
PHST- 2009/01/14 00:00 [accepted]
PHST- 2009/02/03 09:00 [entrez]
PHST- 2009/02/03 09:00 [pubmed]
PHST- 2009/06/11 09:00 [medline]
AID - 10.1007/s00384-009-0655-9 [doi]
PST - ppublish
SO  - Int J Colorectal Dis. 2009 Jun;24(6):677-85. doi: 10.1007/s00384-009-0655-9. Epub 
      2009 Jan 30.